Trial Profile
A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Efavirenz; Lamivudine/zidovudine
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms MERIT; MERIT-ES
- Sponsors ViiV Healthcare
- 07 Sep 2018 Results published in the Journal of Clinical Pharmacology
- 27 Oct 2017 Results of post-hoc analysis (n=895) assessing the effect of maraviroc versus efavirenz on the CD4/CD8 ratio dynamics, presented at the 16th European AIDS Conference.
- 09 Oct 2017 Results (n=721) of post-hoc analysis of Merit study (NCT00098293, NCT03178084), published in the Antimicrobial Agents and Chemotherapy Journal.